Related Experiment Video
Updated: May 22, 2026

Establishment of a Surgically-induced Model in Mice to Investigate the Protective Role of Progranulin in Osteoarthritis
Published on: February 25, 2014
Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage
Katherine R Smith1, John Damiano, Silvana Franceschetti
1Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
A novel mutation in the progranulin gene (GRN) causes neuronal ceroid lipofuscinosis (NCL) in its homozygous state. This finding links NCL to frontotemporal lobar degeneration (FTLD-TDP), typically caused by heterozygous GRN mutations.
Area of Science:
- Genetics
- Neuroscience
- Molecular Biology
Background:
- Neuronal ceroid lipofuscinosis (NCL) is a group of rare lysosomal storage disorders.
- Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) is a common early-onset dementia.
- Heterozygous mutations in the progranulin gene (GRN) are a primary cause of FTLD-TDP.
Purpose of the Study:
- To identify the genetic cause of NCL in a family with two affected siblings.
- To investigate the phenotypic spectrum of progranulin gene mutations.
Main Methods:
- Hypothesis-free linkage analysis and exome sequencing were performed.
- Genetic analysis identified homozygous mutations in the GRN gene.
- Progranulin-deficient mouse models were re-examined.
Main Results:
- Two siblings with NCL were found to be homozygous for a novel c.813_816del mutation in GRN.
- This mutation was located within a linkage peak on chromosome 17.
- Progranulin-deficient mice exhibited neuropathological features consistent with NCL.
Conclusions:
- Homozygous GRN mutations can cause NCL, a distinct neurological disorder from FTLD-TDP.
- This study reveals an unexpected link between NCL and FTLD-TDP.
- GRN mutations exhibit pleiotropic effects depending on heterozygous or homozygous states.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pleiotropy
Principles of Pharmacogenetics: Types of Genetic Variants

